Search results for "Lemi"

showing 10 items of 513 documents

Prediction of dilutional acidosis based on the revised classical dilution concept for bicarbonate

2004

Due to the controversy surrounding the term dilutional acidosis, the classical dilution concept for bicarbonate has been rigorously revised for the prediction of pH, actual bicarbonate concentration, and base excess. In the algorithms derived for buffer solutions, blood, and whole body (1-, 2-, and 3-fluid compartment), only bicarbonate is considered. On dilution at constant Pco2, the final concentration of bicarbonate is the sum in terms of pH, due to the following processes: dilution, formation from chemical reaction with the nonbicarbonate buffers phosphate, hemoglobin, and plasma proteins, and transfer from erythrocytes and interstitial fluid to plasma. At constant Pco2, the level of c…

medicine.medical_specialtyMetabolic Clearance RatePhysiologyBicarbonateVolume replacementIndicator Dilution TechniquesModels Biologicalchemistry.chemical_compoundPhysiology (medical)Volume expansionBicarbonate buffering systemmedicineAnimalsHumansComputer SimulationTissue DistributionDiagnosis Computer-AssistedAcidosisChemistryAcute normovolemic hemodilutionMetabolic disorderHydrogen-Ion ConcentrationPrognosismedicine.diseaseSurgeryDilutionBicarbonatesModels ChemicalAnesthesiamedicine.symptomAcidosisAlgorithmsJournal of Applied Physiology
researchProduct

Monitoring and use of antimycotic (micafungin) for systemic use provided by the pharmacy of Marsala Hospital, Italy

2016

Micafungin is an antimycotic drug and represents an important addition to the available therapies for the treatment of systemic fungal infections. Micafungin is used: in the treatment of invasive candidiasis, oesophageal and prophylaxis of <em>Candida</em> infections. It inhibits, in a non-competitive way, the synthesis of 1,3-β-D-glucan, a component of fungal cell wall and is rapidly distributed into the tissues. It has a high-rate respectful bond with plasma protein, which is independent from the concentration of the drug. It is metabolized through the liver, being not subject to intense metabolic transformations until the excretion. There is no evidence of systemic accumulati…

medicine.medical_specialtyNauseaAnemiaPharmacyPlant SciencePharmacyGeneral Biochemistry Genetics and Molecular BiologyHypomagnesemiaExcretion03 medical and health sciencesHospital Pharmacy0302 clinical medicine030225 pediatricsInternal medicineIntensive caremedicineAntimycotic030212 general & internal medicineSicilylcsh:QH301-705.5Antimycotic; Micafungin; Hospital Pharmacybusiness.industryBiochemistry (medical)Micafunginmedicine.diseaseHypokalemiaSurgerylcsh:Biology (General)MicafunginSettore BIO/14 - Farmacologiamedicine.symptombusinessmedicine.drug
researchProduct

Nitric oxide in the pathogenesis of vascular disease

2000

Nitric oxide (NO) is synthesized by at least three distinct isoforms of NO synthase (NOS). Their substrate and cofactor requirements are very similar. All three isoforms have some implications, physiological or pathophysiological, in the cardiovascular system. The endothelial NOS III is physiologically important for vascular homeostasis, keeping the vasculature dilated, protecting the intima from platelet aggregates and leukocyte adhesion, and preventing smooth muscle proliferation. Central and peripheral neuronal NOS I may also contribute to blood pressure regulation. Vascular disease associated with hypercholesterolaemia, diabetes, and hypertension is characterized by endothelial dysfunct…

medicine.medical_specialtyNitric Oxide Synthase Type IIIHypercholesterolemiaNitric Oxide Synthase Type IIVasodilationNitric OxideEndothelial NOSPathology and Forensic MedicineNitric oxidePathogenesischemistry.chemical_compoundInternal medicineHumansMedicineEndothelial dysfunctionbiologybusiness.industryVascular diseasemedicine.diseaseNitric oxide synthaseEndothelial stem cellOxidative StressEndocrinologychemistryCardiovascular DiseasesHypertensionbiology.proteinEndothelium VascularNitric Oxide SynthasebusinessDiabetic AngiopathiesThe Journal of Pathology
researchProduct

Hypercholesterolemia and haemostatic function changes

1990

Patients with hypercholesterolemia have elevated levels of LDL and reduced plasma concentration of HDL.

medicine.medical_specialtyPlatelet aggregationbusiness.industrynutritional and metabolic diseasesHaemostatic functionFamilial hypercholesterolemiamedicine.diseasePlatelet reactivityEndocrinologyInternal medicinePlasma concentrationMedicinelipids (amino acids peptides and proteins)Platelet activationbusiness
researchProduct

Translational Research for Improving the Care of Familial Hypercholesterolemia: The “Ten Countries Study” and Beyond

2016

Familial hypercholesterolemia (FH) is the most common and serious form of inherited hyperlipidaemia. Dominantly inherited with high penetrance, untreated FH leads to premature death from coronary artery disease due to accelerated atherosclerosis from birth. Despite its importance, there is still a major shortfall in awareness, detection and treatment of FH worldwide. International models of care for FH have recently been published, but their effective implementation requires the garnering of more knowledge about the condition. The "Ten Countries Study" aims to investigate diagnostic, epidemiological and service aspects, as well as physician practices and patient experiences of FH in several…

medicine.medical_specialtyPrevalenceAlternative medicineTranslational researchReviewFamilial hypercholesterolemia030204 cardiovascular system & hematologyHyperlipoproteinemia Type IITranslational Research BiomedicalCoronary artery disease03 medical and health sciences0302 clinical medicineEpidemiologyInternal MedicinemedicineHumans030212 general & internal medicineQuality of Health Carebusiness.industryBiochemistry (medical)medicine.diseaseFamily medicinePhysical therapyObservational studyPersonal experienceCardiology and Cardiovascular MedicinebusinessJournal of Atherosclerosis and Thrombosis
researchProduct

Effect of histamine on the longitudinal and circular muscle of the oestrogen dominated rat uterus.

1993

The response of the longitudinal and circular myometrial strips to histamine was studied in oestrogen-treated rats. Histamine produced a dose-related inhibitory response in KCl-contracted longitudinal and circular uterine strips. Histamine was equipotent in producing the relaxant response but the maximal effect achieved in the longitudinal muscle was higher than the circular one. Ranitidine antagonized the histamine-induced relaxation with a similar dose ratio in both longitudinal and circular strips. Clemizole and reserpine treatment did not produce any modification of the dose-response curve to histamine. In the longitudinal and circular strips which were not preconstricted by KCl, neithe…

medicine.medical_specialtyReserpinePyridinesMuscle RelaxationImmunologyUterusBiologyIn Vitro TechniquesToxicologyInhibitory postsynaptic potentialRanitidinePotassium ChlorideRanitidineHistamine Agonistschemistry.chemical_compoundUterine ContractionInternal medicinemedicineAnimalsPharmacology (medical)Receptors Histamine H2Rats WistarPharmacologyUterusEstrogensMuscle SmoothReserpineClemizoleRatsmedicine.anatomical_structureEndocrinologychemistryIn uteroBenzimidazolesFemalemedicine.symptomHistaminemedicine.drugMuscle contractionHistamineAgents and actions
researchProduct

Current insights into the German lipoprotein apheresis standard: PCSK9-inhibitors, lipoprotein apheresis or both?

2017

Abstract According to current European guidelines, lipid lowering therapy for progressive cardiovascular disease including cardiovascular events has to be focused on a target level for LDL-C. In contrast for Lp(a) a threshold has to be defined with respect to the method of measurement. However, due to new lipid lowering drug developments like PCSK9-inhibitors (PCSK-9-I) a therapeutic algorithm for patients with severe hypercholesterolemia or isolated Lipoprotein(a)-hyperlipoproteinemia with progressive cardiovascular disease may be necessary to manage the use of PCSK9-I, lipoprotein apheresis (LA) or both. The therapeutic approach for patients with homozygous familial hypercholesterolemia i…

medicine.medical_specialtySerine Proteinase InhibitorsDiseaseFamilial hypercholesterolemia030204 cardiovascular system & hematologyRisk AssessmentHyperlipoproteinemia Type II03 medical and health sciencesTherapeutic approach0302 clinical medicineRisk FactorsInternal medicineGermanyInternal MedicinemedicineHumans030212 general & internal medicinePCSK9 Inhibitorsbiologybusiness.industryPCSK9Anticholesteremic AgentsPCSK9 InhibitorsGeneral MedicineLipoprotein(a)Cholesterol LDLmedicine.diseaseCombined Modality TherapyEndocrinologyTreatment OutcomeCardiovascular Diseasesbiology.proteinCardiologyBlood Component Removallipids (amino acids peptides and proteins)Proprotein Convertase 9Cardiology and Cardiovascular MedicinebusinessLipoprotein apheresisBiomarkersLipoproteinLipoprotein(a)Atherosclerosis. Supplements
researchProduct

Beyond Statins: New Lipid Lowering Strategies to Reduce Cardiovascular Risk

2014

Statins are the first-line therapy in LDL-Cholesterol (LDL-C) reduction and its clinical use has contributed to significant prevention and treatment of atherosclerotic vascular disease. Yet, a significant proportion of patients remain at high risk. Recently, a number of new therapies have been developed to further lower LDL-C. These agents may provide clinical benefit on top of statin therapy in patients with high residual risk, severe hypercholesterolemia or as an alternative for patients who are intolerant to statins. We review four novel approaches based on the inhibition of proprotein convertase subtilisin/kexin type 9 (PCSK9), apolipoprotein-B100 (apoB), Cholesteryl ester transport pro…

medicine.medical_specialtySettore MED/09 - Medicina InternaApolipoprotein BHypercholesterolemiaMipomersenFamilial hypercholesterolemiaBioinformaticschemistry.chemical_compoundRisk FactorsAnacetrapibInternal medicinemedicineHumansStatins Novel LDL-C lowering drugs Mipomersen Lomitapide Anacetrapib Evacetrapib PCSK9 inhibitorsbiologybusiness.industryAnticholesteremic AgentsPCSK9nutritional and metabolic diseasesLipid Metabolismmedicine.diseaseLomitapideResidual riskEndocrinologychemistryCardiovascular Diseasesbiology.proteinlipids (amino acids peptides and proteins)Hydroxymethylglutaryl-CoA Reductase InhibitorsCardiology and Cardiovascular MedicinebusinessEvacetrapibCurrent Atherosclerosis Reports
researchProduct

Genetically determined hypercholesterolaemia results into premature leucocyte telomere length shortening and reduced haematopoietic precursors

2020

Abstract Aims Leucocyte telomere length (LTL) shortening is a marker of cellular senescence and associates with increased risk of cardiovascular disease (CVD). A number of cardiovascular risk factors affect LTL, but the correlation between elevated LDL cholesterol (LDL-C) and shorter LTL is debated: in small cohorts including subjects with a clinical diagnosis of familial hypercholesterolaemia (FH). We assessed the relationship between LDL-C and LTL in subjects with genetic familial hypercholesterolaemia (HeFH) compared to those with clinically diagnosed, but not genetically confirmed FH (CD-FH), and normocholesterolaemic subjects. Methods and results LTL was measured in mononuclear cells-d…

medicine.medical_specialtySettore MED/09 - Medicina InternaCellular ageingEpidemiologyHypercholesterolemiaCD34Cellular senescence030204 cardiovascular system & hematologyHyperlipoproteinemia Type II03 medical and health sciencesMice0302 clinical medicineInternal medicineLeukocytesMedicineAnimalsHumansProgenitor cellHaematopoiesi030304 developmental biologyLdl cholesterol0303 health sciencesbusiness.industryCholesterol LDLTelomere3. Good healthTelomereHaematopoiesisIncreased riskEndocrinologymedicine.anatomical_structureCHDTelomeresBone marrowCardiology and Cardiovascular MedicinebusinessFamilial hypercholesterolaemia
researchProduct

Long-term efficacy of lipoprotein apheresis and lomitapide in the treatment of homozygous familial hypercholesterolemia (HoFH): a cross-national retr…

2021

Abstract Background Homozygous familial hypercholesterolemia (HoFH) is a rare life-threatening condition that represents a therapeutic challenge. The vast majority of HoFH patients fail to achieve LDL-C targets when treated with the standard protocol, which associates maximally tolerated dose of lipid-lowering medications with lipoprotein apheresis (LA). Lomitapide is an emerging therapy in HoFH, but its place in the treatment algorithm is disputed because a comparison of its long-term efficacy versus LA in reducing LDL-C burden is not available. We assessed changes in long-term LDL-C burden and goals achievement in two independent HoFH patients’ cohorts, one treated with lomitapide in Ita…

medicine.medical_specialtySettore MED/09 - Medicina Interna[SDV]Life Sciences [q-bio]LipoproteinsGenetic diseaseTherapeuticsFamilial hypercholesterolemiaDiseaseLipoprotein apheresiLDLHyperlipoproteinemia Type IIchemistry.chemical_compoundLipoprotein apheresisRetrospective surveyInternal medicineCholesterol burden; Genetic disease; Homozygous hypercholesterolemia; LDL; Lipoprotein apheresis; Lomitapide; Therapeutics; Benzimidazoles; Homozygote; Humans; Lipoproteins; Retrospective Studies; Anticholesteremic Agents; Blood Component Removal; Hyperlipoproteinemia Type IImedicineHumansPharmacology (medical)Genetics (clinical)Retrospective Studiesmedicine.diagnostic_testbusiness.industryResearchAnticholesteremic AgentsHomozygous hypercholesterolemiaHomozygoteRGeneral Medicinemedicine.diseaseLomitapideLomitapidecholesterol burden; genetic disease; homozygous hypercholesterolemia; LDL; lipoprotein apheresis; lomitapide; therapeuticsCholesterol burdenchemistryCohortBlood Component RemovalMedicineTherapeutics.BenzimidazolesLipid profilebusinessLipoprotein apheresisCross nationalOrphanet Journal of Rare Diseases
researchProduct